Objective

To investigate the therapeutic outcomes of chemotherapy with infusion related HLA-mismatched hematopoietic stem cells for hematologic malignancies.

Method

Therapy responses and hematopoietic recovery as well as complications of 9 patients were analyzed.

Result

In the 9 patients aged 29-67 years, four were acute myeloid leukemia, one was acute B lymphocytic leukemia, two were multiple myeloma, one was Hodgkin’s disease, one was diffuse large B cell lymphoma. The average MNC was (3.12±1.29)×108/kg, CD34+ cells was (1.71± 1.00)×106/kg, CD3+ cells was (2.13±0.99)×108/kg. There was complete remission in four patients, partial remission in one, disease progression in four. Following up 2 to 14 months, four patients was in survival. No donor chimerism was detected and no graft-versus-host disease was observed in any patient.

Conclusion

Chemotherapy with infusion related HLA-mismatched hematopoietic stem cells for hematologic malignancies may provide a promising treatment method as a novel therapeutic strategy.

Disclosures:

No relevant conflicts of interest to declare.

Topics:
chemotherapy regimen, hematologic neoplasms, hematopoietic stem cells, human leukocyte antigens, infusion procedures, mismatch, cd34 antigens, chronic lymphocytic leukemia, complete remission, diffuse large b-cell lymphoma

Author notes

*

Asterisk with author names denotes non-ASH members.

© 2013 by The American Society of Hematology
2013
Sign in via your Institution